A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension.
Phase of Trial: Phase III
Latest Information Update: 01 Jan 2016
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Chlortalidone; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions; Registrational
- Sponsors Takeda; Takeda Global Research and Development Center
- 19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2010 Actual patient number (669) added as reported by ClinicalTrials.gov.
- 19 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.